Cargando…

Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals

BACKGROUND: An effective yellow fever (YF) vaccine has been available since 1937. Nevertheless, questions regarding its use remain poorly understood, such as the ideal dose to confer immunity against the disease, the need for a booster dose, the optimal immunisation schedule for immunocompetent, imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonin, Carla Rezende Barbosa, Fernandes, Guilherme Côrtes, de Menezes Martins, Reinaldo, Camacho, Luiz Antonio Bastos, Teixeira-Carvalho, Andréa, da Mota, Licia Maria Henrique, de Lima, Sheila Maria Barbosa, Campi-Azevedo, Ana Carolina, Martins-Filho, Olindo Assis, dos Santos, Rodrigo Weber, Lobosco, Marcelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733702/
https://www.ncbi.nlm.nih.gov/pubmed/33308151
http://dx.doi.org/10.1186/s12859-020-03845-3
_version_ 1783622327898996736
author Bonin, Carla Rezende Barbosa
Fernandes, Guilherme Côrtes
de Menezes Martins, Reinaldo
Camacho, Luiz Antonio Bastos
Teixeira-Carvalho, Andréa
da Mota, Licia Maria Henrique
de Lima, Sheila Maria Barbosa
Campi-Azevedo, Ana Carolina
Martins-Filho, Olindo Assis
dos Santos, Rodrigo Weber
Lobosco, Marcelo
author_facet Bonin, Carla Rezende Barbosa
Fernandes, Guilherme Côrtes
de Menezes Martins, Reinaldo
Camacho, Luiz Antonio Bastos
Teixeira-Carvalho, Andréa
da Mota, Licia Maria Henrique
de Lima, Sheila Maria Barbosa
Campi-Azevedo, Ana Carolina
Martins-Filho, Olindo Assis
dos Santos, Rodrigo Weber
Lobosco, Marcelo
author_sort Bonin, Carla Rezende Barbosa
collection PubMed
description BACKGROUND: An effective yellow fever (YF) vaccine has been available since 1937. Nevertheless, questions regarding its use remain poorly understood, such as the ideal dose to confer immunity against the disease, the need for a booster dose, the optimal immunisation schedule for immunocompetent, immunosuppressed, and pediatric populations, among other issues. This work aims to demonstrate that computational tools can be used to simulate different scenarios regarding YF vaccination and the immune response of individuals to this vaccine, thus assisting the response of some of these open questions. RESULTS: This work presents the computational results obtained by a mathematical model of the human immune response to vaccination against YF. Five scenarios were simulated: primovaccination in adults and children, booster dose in adult individuals, vaccination of individuals with autoimmune diseases under immunomodulatory therapy, and the immune response to different vaccine doses. Where data were available, the model was able to quantitatively replicate the levels of antibodies obtained experimentally. In addition, for those scenarios where data were not available, it was possible to qualitatively reproduce the immune response behaviours described in the literature. CONCLUSIONS: Our simulations show that the minimum dose to confer immunity against YF is half of the reference dose. The results also suggest that immunological immaturity in children limits the induction and persistence of long-lived plasma cells are related to the antibody decay observed experimentally. Finally, the decay observed in the antibody level after ten years suggests that a booster dose is necessary to keep immunity against YF.
format Online
Article
Text
id pubmed-7733702
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77337022020-12-14 Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals Bonin, Carla Rezende Barbosa Fernandes, Guilherme Côrtes de Menezes Martins, Reinaldo Camacho, Luiz Antonio Bastos Teixeira-Carvalho, Andréa da Mota, Licia Maria Henrique de Lima, Sheila Maria Barbosa Campi-Azevedo, Ana Carolina Martins-Filho, Olindo Assis dos Santos, Rodrigo Weber Lobosco, Marcelo BMC Bioinformatics Research BACKGROUND: An effective yellow fever (YF) vaccine has been available since 1937. Nevertheless, questions regarding its use remain poorly understood, such as the ideal dose to confer immunity against the disease, the need for a booster dose, the optimal immunisation schedule for immunocompetent, immunosuppressed, and pediatric populations, among other issues. This work aims to demonstrate that computational tools can be used to simulate different scenarios regarding YF vaccination and the immune response of individuals to this vaccine, thus assisting the response of some of these open questions. RESULTS: This work presents the computational results obtained by a mathematical model of the human immune response to vaccination against YF. Five scenarios were simulated: primovaccination in adults and children, booster dose in adult individuals, vaccination of individuals with autoimmune diseases under immunomodulatory therapy, and the immune response to different vaccine doses. Where data were available, the model was able to quantitatively replicate the levels of antibodies obtained experimentally. In addition, for those scenarios where data were not available, it was possible to qualitatively reproduce the immune response behaviours described in the literature. CONCLUSIONS: Our simulations show that the minimum dose to confer immunity against YF is half of the reference dose. The results also suggest that immunological immaturity in children limits the induction and persistence of long-lived plasma cells are related to the antibody decay observed experimentally. Finally, the decay observed in the antibody level after ten years suggests that a booster dose is necessary to keep immunity against YF. BioMed Central 2020-12-14 /pmc/articles/PMC7733702/ /pubmed/33308151 http://dx.doi.org/10.1186/s12859-020-03845-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bonin, Carla Rezende Barbosa
Fernandes, Guilherme Côrtes
de Menezes Martins, Reinaldo
Camacho, Luiz Antonio Bastos
Teixeira-Carvalho, Andréa
da Mota, Licia Maria Henrique
de Lima, Sheila Maria Barbosa
Campi-Azevedo, Ana Carolina
Martins-Filho, Olindo Assis
dos Santos, Rodrigo Weber
Lobosco, Marcelo
Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals
title Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals
title_full Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals
title_fullStr Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals
title_full_unstemmed Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals
title_short Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals
title_sort validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733702/
https://www.ncbi.nlm.nih.gov/pubmed/33308151
http://dx.doi.org/10.1186/s12859-020-03845-3
work_keys_str_mv AT bonincarlarezendebarbosa validationofayellowfevervaccinemodelusingdatafromprimaryvaccinationinchildrenandadultsrevaccinationanddoseresponseinadultsandstudieswithimmunocompromisedindividuals
AT fernandesguilhermecortes validationofayellowfevervaccinemodelusingdatafromprimaryvaccinationinchildrenandadultsrevaccinationanddoseresponseinadultsandstudieswithimmunocompromisedindividuals
AT demenezesmartinsreinaldo validationofayellowfevervaccinemodelusingdatafromprimaryvaccinationinchildrenandadultsrevaccinationanddoseresponseinadultsandstudieswithimmunocompromisedindividuals
AT camacholuizantoniobastos validationofayellowfevervaccinemodelusingdatafromprimaryvaccinationinchildrenandadultsrevaccinationanddoseresponseinadultsandstudieswithimmunocompromisedindividuals
AT teixeiracarvalhoandrea validationofayellowfevervaccinemodelusingdatafromprimaryvaccinationinchildrenandadultsrevaccinationanddoseresponseinadultsandstudieswithimmunocompromisedindividuals
AT damotaliciamariahenrique validationofayellowfevervaccinemodelusingdatafromprimaryvaccinationinchildrenandadultsrevaccinationanddoseresponseinadultsandstudieswithimmunocompromisedindividuals
AT delimasheilamariabarbosa validationofayellowfevervaccinemodelusingdatafromprimaryvaccinationinchildrenandadultsrevaccinationanddoseresponseinadultsandstudieswithimmunocompromisedindividuals
AT campiazevedoanacarolina validationofayellowfevervaccinemodelusingdatafromprimaryvaccinationinchildrenandadultsrevaccinationanddoseresponseinadultsandstudieswithimmunocompromisedindividuals
AT martinsfilhoolindoassis validationofayellowfevervaccinemodelusingdatafromprimaryvaccinationinchildrenandadultsrevaccinationanddoseresponseinadultsandstudieswithimmunocompromisedindividuals
AT dossantosrodrigoweber validationofayellowfevervaccinemodelusingdatafromprimaryvaccinationinchildrenandadultsrevaccinationanddoseresponseinadultsandstudieswithimmunocompromisedindividuals
AT loboscomarcelo validationofayellowfevervaccinemodelusingdatafromprimaryvaccinationinchildrenandadultsrevaccinationanddoseresponseinadultsandstudieswithimmunocompromisedindividuals
AT validationofayellowfevervaccinemodelusingdatafromprimaryvaccinationinchildrenandadultsrevaccinationanddoseresponseinadultsandstudieswithimmunocompromisedindividuals